Conducting Clinical Trials Part 2: Avoiding Mistaken Public Disclosures

Clinical trials have found their way into the spotlight of the coronavirus pandemic as multiple pharmaceutical and biotechnology companies race to develop and market vaccines and therapies. As breakthrough technologies are on the rise, so are the risks associated with vaccine and drug development. “Conducting Clinical Trials” is a podcast miniseries featuring Choate attorneys covering a number of topics related to clinical trials, including common mistakes companies make along the way and various strategic choices they face.

When a company does not maintain proper hygiene in its disclosure practices, the risk of mistakenly releasing clinical trial data, product formulation information, or information about a product’s mechanism of action becomes almost inevitable. In this episode of Choate’s Conducting Clinical Trials series, Christine Savage and Eric Marandett cover issues that can arise when there is premature or mistaken public disclosure of sensitive clinical trial information and discuss strategies companies can use to minimize the likelihood of encountering issues from inadvertently releasing information.

Listen to additional episodes →